Imugene Ltd has released a press release.
First Patients Dosed in Combination Study of VAXINIA
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from Imugene
- Imugene PD1-Vaxx Immunotherapy Patent Granted in the US
- Imugene VAXINIA trial advances to Combination Cohort
- Imugene Receives Vaxinia Ethics Approval in Australia
- CHECKVacc Data Presented at the 2022 SABC Symposium
- First Patient Dosed in VAXINIA Intravenous Cohort 2
Later from Imugene
- First patients dosed in IT & IV cohort 3 of VAXINIA trial
- Imugene Images and Follows CHECKVacc in TNBC Patients
- Imugene receives $12.6m R&D tax refund
- onCARlytics with Artemis T cells abstract presented at ASGCT
- onCARlytics with ARTEMIS T cells show anti-tumour activity
Follow Imugene into a list and get an email when it puts out news.
Follow Imugene